Category
LEUKOTRIENE RECEPTOR ANTAGONISTS (LTRAS)
LEUKOTRIENE RECEPTOR ANTAGONISTS (LTRAS)
Consistent
Purity
Global-Ready
Molecules
Advanced
Manufacturing
Scalable
Production
Partnership
Support
Montelukast Sodium API has been developed by ASANA Pharmaceutical as part of its respiratory care portfolio. Montelukast Sodium API, listed under CAS number 158966-92-8, is a leukotriene receptor antagonist (LTRA) widely used in the prevention and treatment of asthma and allergic rhinitis.
ASANA Pharmaceutical is focused on the development and production of high-purity respiratory care APIs such as Montelukast Sodium. With specialized capabilities in leukotriene pathway inhibitors and a commitment to global regulatory compliance, ASANA serves pharmaceutical companies across North America, Europe, and Asia. Our advanced infrastructure ensures stable supply, scalability, and reliable therapeutic performance.
ASANA Pharmaceutical actively collaborates with formulation partners, CROs, and regulatory consultants, bringing together expertise in respiratory science, analytical precision, and process optimization to remain competitive in the global market. Montelukast Sodium [CAS No. 158966-92-8], a Leukotriene Receptor Antagonist (LTRA), plays a vital role in the management of asthma and allergic rhinitis, and is a key part of ASANA’s respiratory portfolio. As awareness grows around chronic respiratory disorders, ASANA is committed to delivering:
Montelukast Sodium API are available on public databases such as Wikipedia. Wikipidia!